nach Quartalsbericht mit deutlich reduziertem Verlust und mehreren Kaufempfehlungen Kursziel 17$,Stochstik bereits relativ hoch Alert: UBS Warburg reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:49 PM EDT
• Alert: First Union Sec reiterates coverage of ORCH at Strong Buy (Headline only) Briefing.com - 12:42 PM EDT
• Alert: Robertson Stephens reiterates coverage of ORCH at Buy (Headline only) Briefing.com - 12:32 PM EDT
Orchid BioSciences, Inc. (Nasdaq: ORCH) Previous Close: Up 16% to $4.75 on vol.
2,167,400 Shares: ACCUMULATE
Orchid BioSciences, Inc. (Nasdaq: ORCH) announced that it has successfully
performed ultra-high throughput genotyping using its proprietary SNP-IT(TM) SNP
scoring technology on two different instrument platforms. Orchid is the first
company to demonstrate the feasibility of ultra-high throughput SNP scoring on
multiple platforms. Both systems serve as scalable components of Orchid's
MegaSNPatron(TM) facilities that provide SNP scoring services primarily for high
volume users like pharmaceutical and agricultural companies.
Orchid BioSciences recently reported financial results for its first quarter
ended March 31, 2001. Total revenues for the first quarter of 2001 increased to
$5.6 million, up from $3.5 million for the same period in 2000, an increase of
60 percent. The increase in revenues during the first quarter resulted primarily
from placements of SNPstream(R) 25K platforms, sales of SNPware(TM) consumable
kits, sales of single nucleotide polymorphism (SNP) scoring and DNA and other
genetic diversity testing services, collaboration and license fees, and the
addition of Cellmark Diagnostics, which Orchid acquired in February, 2001.
Orchid BioSciences, Inc. is a leading provider of products, services and
technologies for SNP scoring and genetic diversity analyses. Orchid has
developed SNP-IT, its proprietary SNP analysis technology and markets SNPstream
instruments and SNPware(TM) consumables that rapidly generate highly accurate,
cost effective SNP information. SNP-IT is usable in environments ranging from
small-scale laboratories to large commercial facilities. Its versatility also
has enabled Orchid to partner with industry leaders to make SNP-IT-enabled
products available on a wide variety of instrument platforms.
Allerdings neues SECFiling über geplante Kapitalerhöhung!